Please assess the completion status of the following clinical trial:

Trial Title: MTX Discontinuation and Vaccine Response

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Males or females \> 18 years at time of consent~* Have a diagnosis of RA per ACR criteria~* Must understand and voluntarily sign an informed consent form including writing consent for data protection~* Stable doses of methotrexate over the preceding 6 weeks~Exclusion Criteria:~* Pregnant or lactating females~* Previous anaphylactic response to vaccine components or to egg.~* Acute infection with T \>38°C at the time of vaccination~* History of Guillain-Barre syndrome or demyelinating syndromes~* Previous vaccination with any live vaccine 4 weeks before or any inactivated vaccine 2 weeks before the study~* Blood transfusion within 6 months~* Active rheumatoid arthritis necessitating a recent change in the drug regimen~* Any other rheumatic disease such as systemic lupus erythematosus, mixed connective tissue disease, dermatomyositis/polymyositis, and vasculitis except for secondary Sjogren's disease

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Group 1 (No MTX Hold before Vaccination) (Type: EXPERIMENTAL): Group 1 will continue MTX
- Group 2 (MTX hold 4 Weeks before vaccination) (Type: EXPERIMENTAL): Group 2 will hold MTX 4 weeks before vaccination and resume MTX on the day of vaccination
- Group 3 (MTX hold 2 Weeks before Vaccination) (Type: EXPERIMENTAL): Group 3 will hold MTX 2 weeks before vaccination and resume MTX 2 weeks after vaccination
- Group 4 (MTX hold on Day of Vaccination) (Type: EXPERIMENTAL): Group 4 will hold MTX on day of vaccination and resume MTX 4 weeks after vaccination.

Based on this trial design, predict the completion outcome and termination type (if applicable).